Latest News

Cemiplimab Improves Survival in NSCLC with Brain Metastases and High PD-L1
Cemiplimab Improves Survival in NSCLC with Brain Metastases and High PD-L1

May 16th 2025

First-line cemiplimab showed improved survival vs chemotherapy in advanced NSCLC with brain metastases and PD-L1 ≥50% in EMPOWER-Lung 1.

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference
Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

May 16th 2025

Studies Find Supportive Care Approaches for Amivantamab in Lung Cancer
Studies Find Supportive Care Approaches for Amivantamab in Lung Cancer

May 15th 2025

Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC
Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC

May 15th 2025

FDA Grants Telisotuzumab Vedotin Accelerated Approval in c-MET+  NSCLC
FDA Grants Telisotuzumab Vedotin Accelerated Approval in c-MET+ NSCLC

May 14th 2025

More News